S Syndax Pharmaceuticals
| Market Cap | $2.22B |
| P/E Ratio | — |
| Forward P/E | -42.10 |
| Dividend Yield | — |
| Beta | 0.41 |
| 52W Range | $8.73 - $25.15 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Torray Funds Torray Investment Partners | 0.29% | $2.05M | 97,802 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 8 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Metzger Michael AChief Executive Officer | Sale | 17,159 | $21.03 | $360.82K | 09 Feb 2026 | 10 Feb 2026 |
| Goldan Keith A.Chief Financial Officer | Sale | 3,410 | $21.03 | $71.71K | 09 Feb 2026 | 10 Feb 2026 |
| Keith A. GoldanChief Financial Officer | Sale | 3,410 | $21.03 | $71.71K | 09 Feb 2026 | 10 Feb 2026 |
| Michael A MetzgerChief Executive Officer | Sale | 17,159 | $21.03 | $360.82K | 09 Feb 2026 | 10 Feb 2026 |
| Metzger Michael AChief Executive Officer | Sale | 7,412 | $20.62 | $152.84K | 06 Feb 2026 | 06 Feb 2026 |
| Goldan Keith A.Chief Financial Officer | Sale | 2,082 | $20.62 | $42.93K | 06 Feb 2026 | 06 Feb 2026 |
| Michael A MetzgerChief Executive Officer | Sale | 7,412 | $20.62 | $152.84K | 06 Feb 2026 | 06 Feb 2026 |
| Keith A. GoldanChief Financial Officer | Sale | 2,082 | $20.62 | $42.93K | 06 Feb 2026 | 06 Feb 2026 |
Frequently Asked Questions
What is SNDX stock price today?
Syndax Pharmaceuticals (SNDX) is currently trading at $25.15. The stock has a 52-week range of $8.73 to $25.15 and a market capitalization of $2.22B.
Is SNDX a good stock to buy in 2026?
Syndax Pharmaceuticals has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +101.8%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling SNDX stock?
There have been 8 insider transactions for SNDX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has SNDX stock performed over the past year?
Syndax Pharmaceuticals (SNDX) has returned +101.8% over the past 12 months. The stock traded between $8.73 and $25.15 during this period, and is currently at $25.15.
Which hedge funds own SNDX (Syndax Pharmaceuticals)?
1 tracked hedge funds currently hold SNDX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is SNDX's market cap and valuation?
Syndax Pharmaceuticals (SNDX) has a market capitalization of $2.22B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is SNDX's revenue and profitability?
Syndax Pharmaceuticals reported revenue of $172.35M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.41.
What sector is SNDX in and who are its biggest institutional holders?
Syndax Pharmaceuticals (SNDX) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.